Skip to main content
LLM 2023 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Session III: AML and MDS

Debate: All Non-FLT3 Mutated AML Patients Above Age 60 with ELN Intermediate or Adverse Risk Should Be Treated with Azacitidine and Venetoclax - NO

Wednesday, October 18, 2023
3:00 PM – 3:15 PM ET
Location: Metropolitan East

    Debate Speaker(s)

  • Tapan Kadia, MD

    MD Anderson Cancer Center
    Bellaire, Texas, United States